Sunday, July 06, 2025 10:43:17 PM
When the MHRA requests an RFI from a company that submitted a MAA to the MHRA, does the MHRA return the entire MAA to the company
until it receives a comprehensive response that addresses all the questions raised by the RFI?
AI Overview.
" No, when the MHRA sends a Request for Information (RFI) to a company that submitted a Marketing Authorisation Application (MAA), the MHRA does not return the entire MAA to the company.
Instead, the MHRA sends a letter detailing the specific information or clarifications needed to continue with the assessment. This RFI will be a consolidated list of questions covering all relevant sections of the dossier.
The company is expected to provide a comprehensive response addressing all the questions raised in the RFI, including any necessary updated documentation. This response should be submitted as an eCTD sequence using the MHRA's RFI response template. The response document should be provided in both PDF and Word (.docx) formats.
The RFI process essentially pauses the clock for the assessment timeline, allowing the company time to gather and submit the required information. Once the complete response to the RFI is received, the clock restarts, and the MHRA continues its assessment.
In summary: The MAA remains with the MHRA, and the company provides a targeted response to the RFI, addressing the specific areas needing further information or clarification"
until it receives a comprehensive response that addresses all the questions raised by the RFI?
AI Overview.
" No, when the MHRA sends a Request for Information (RFI) to a company that submitted a Marketing Authorisation Application (MAA), the MHRA does not return the entire MAA to the company.
Instead, the MHRA sends a letter detailing the specific information or clarifications needed to continue with the assessment. This RFI will be a consolidated list of questions covering all relevant sections of the dossier.
The company is expected to provide a comprehensive response addressing all the questions raised in the RFI, including any necessary updated documentation. This response should be submitted as an eCTD sequence using the MHRA's RFI response template. The response document should be provided in both PDF and Word (.docx) formats.
The RFI process essentially pauses the clock for the assessment timeline, allowing the company time to gather and submit the required information. Once the complete response to the RFI is received, the clock restarts, and the MHRA continues its assessment.
In summary: The MAA remains with the MHRA, and the company provides a targeted response to the RFI, addressing the specific areas needing further information or clarification"
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
